Radionuclide therapy for pancreatic neuroendocrine neoplasms / 中国实用外科杂志
Chinese Journal of Practical Surgery
; (12): 934-938, 2019.
Article
em Zh
| WPRIM
| ID: wpr-816488
Biblioteca responsável:
WPRO
ABSTRACT
Pancreatic neuroendocrine neoplasms(pNENs)are the most common neuroendocrine tumors.For early local pNENs,surgery is the main therapeutic strategy and the tumor can be removed completely.But for those pNENs that cannot be surgically removed or have undergone distant metastasis,peptide receptor radionuclide therapy(PRRT)can be chosen as a first-line therapeutic strategy as pNENs overexpress somatostatin receptors.In recent years,clinical trials and studies on the use of PRRT in pNENs have been increasing rapidly.Many reports have confirmed the efficacy of 90 Y and 177 Lu-labeled somatostatin analogue in pNENs patients.
Texto completo:
1
Índice:
WPRIM
Idioma:
Zh
Revista:
Chinese Journal of Practical Surgery
Ano de publicação:
2019
Tipo de documento:
Article